» Articles » PMID: 36075586

Mediation of the Total Effect of Cystic Fibrosis-related Diabetes on Mortality: A UK Cystic Fibrosis Registry Cohort Study

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2022 Sep 8
PMID 36075586
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To investigate whether the effect of cystic fibrosis-related diabetes (CFRD) on the composite outcome of mortality or transplant could act through lung function, pulmonary exacerbations and/or nutritional status.

Methods: A retrospective cohort of adult cystic fibrosis (CF) patients who had not been diagnosed with CFRD were identified from the UK Cystic Fibrosis Registry (n = 2750). Rate of death or transplant was compared between patients who did and did not develop CFRD (with insulin use) during follow-up using Poisson regression, separately by sex. Causal mediation methods were used to investigate whether lung function, pulmonary exacerbations and nutritional status lie on the causal pathway between insulin-treated CFRD and mortality/transplant.

Results: At all ages, the mortality/transplant rate was higher in both men and women diagnosed with CFRD. Pulmonary exacerbations were the strongest mediator of the effect of CFRD on mortality/transplant, with an estimated 15% [95% CI: 7%, 28%] of the effect at 2 years post-CFRD diagnosis attributed to exacerbations, growing to 24% [95% CI: 9%, 46%] at 4 years post-diagnosis. Neither lung function nor nutritional status were found to be significant mediators of this effect. Estimates were similar but with wider confidence intervals in a cohort that additionally included people with CFRD but not using insulin.

Conclusion: There is evidence that pulmonary exacerbations mediate the effect of CFRD on mortality but, as they are estimated to mediate less than one-quarter of the total effect, the mechanism through which CFRD influences survival may involve other factors.

Citing Articles

What the future holds: cystic fibrosis and aging.

Blankenship S, Landis A, Harrison Williams E, Lever J, Garcia B, Solomon G Front Med (Lausanne). 2024; 10:1340388.

PMID: 38264036 PMC: 10804849. DOI: 10.3389/fmed.2023.1340388.


Continuous Glucose Monitoring as an Additional Tool in Early Cystic Fibrosis-Related Diabetes Monitoring and in Evaluation of Short-Term Sitagliptin Response.

Sebastian-Valles F, Arranz Martin J, Giron R, Knott-Torcal C, Sampedro-Nunez M, Martin-Adan J Biomedicines. 2023; 11(6).

PMID: 37371849 PMC: 10296576. DOI: 10.3390/biomedicines11061754.


Mediation of the total effect of cystic fibrosis-related diabetes on mortality: A UK Cystic Fibrosis Registry cohort study.

Tanner K, Daniel R, Bilton D, Simmonds N, Sharples L, Keogh R Diabet Med. 2022; 39(11):e14958.

PMID: 36075586 PMC: 9826418. DOI: 10.1111/dme.14958.

References
1.
Lanng S, Thorsteinsson B, Nerup J, Koch C . Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992; 151(9):684-7. DOI: 10.1007/BF01957574. View

2.
Simmonds N . Ageing in cystic fibrosis and long-term survival. Paediatr Respir Rev. 2013; 14 Suppl 1:6-9. DOI: 10.1016/j.prrv.2013.01.007. View

3.
Lewis C, Blackman S, Nelson A, Oberdorfer E, Wells D, Dunitz J . Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2014; 191(2):194-200. PMC: 4347432. DOI: 10.1164/rccm.201403-0576OC. View

4.
De Boer K, Vandemheen K, Tullis E, Doucette S, Fergusson D, Freitag A . Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax. 2011; 66(8):680-5. DOI: 10.1136/thx.2011.161117. View

5.
Adler A, Shine B, Chamnan P, Haworth C, Bilton D . Genetic determinants and epidemiology of cystic fibrosis-related diabetes: results from a British cohort of children and adults. Diabetes Care. 2008; 31(9):1789-94. PMC: 2518346. DOI: 10.2337/dc08-0466. View